Search Follow us

Addex Therapeutics (ADXN)

Business description

Addex Therapeutics is a Swiss biotech company with a leading position in the identification of allosteric modulators with activity in CNS, inflammatory and metabolic disease. Its pipeline includes two Phase II compounds, with one partnered with J&J.

Lilly issues may give Addex a boost

Update | Pharmaceutical & healthcare | 30/07/2012

Addex has seen an unexpected boost to the prospects for its lead partnered product, JNJ-40411813, as a result of a trial setback reported recently with Lilly’s pomaglumetad methionil, a mechanistically-close competitor. The news may allow Janssen Pharmaceuticals, Addex’s partner, to catch up with a rival that had hitherto been several years ahead. Both products aim to up-regulate mGluR2, but Lilly’s is an orthosteric mGluR2/3 agonist, while Addex’s is a more selective mGluR2 PAM. Meanwhile J&J is completing its own Phase II study in schizophrenia and is starting a Phase II study in anxiety co-morbid with depression.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF32.9m
Last closeCHF2.140
High / Low (52 weeks)CHF2.5 / CHF1.8
Stock market listingSW
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(4.8)(8.9)(23.3)

* % Relative to local index